Persistence. It cannot be excluded that zoledronic acid is persistent, due to the lack of data.
Bioaccumulation. It cannot be excluded that zoledronic acid bioaccumulates, due to the lack of data.
Toxicity. It cannot be excluded that zoledronic acid is toxic, due to the lack of data.
Risk. Risk of environmental impact of zoledronic acid cannot be excluded, due to the lack of environmental toxicity data.
This summary information comes from Fass. The manufacturer Pfizer has stated on fass.se that the data about the environmental impact is missing for the substance so that the environmental risk cannot be calculated. It is voluntary for manufacturers to provide information on the environmental impact on fass.se.
Fass environmental information
Fass environmental information for Zoledronic Acid Hospira from Pfizer (downloaded 2023-03-01).
Persistence: No data.
Bioaccumulation: No data.
Toxicity: No data.
Risk of environmental impact of zoledronic acid cannot be excluded, due to the lack of environmental toxicity data.
There are assessment reports with environmental information for Zoledronic acid Teva, Zoledronic acid Actavis, Zoledronic Acid Hospira, Zoledronic Acid Accord and Zoledronic acid medac with similar information. The following information is from Zoledronic Acid Accord, 21 November 2013 EMA/806574/2013. "No Environmental Risk Assessment was submitted. This was justified by the applicant as the introduction of Zoledronic Acid Accord manufactured by Accord Healthcare Limited is considered unlikely to result in any significant increase in the combined sales volumes for all zoledronic acid containing products and the exposure of the environment to the active substance. Thus, the ERA is expected to be similar and not increased." However, no environmental information about zoledronic acid has been found on the EMA website (2023-03-01).
Author: Health and Medical Care Administration, Region Stockholm